Elotuzumab

EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.

What it is used for

EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Side effects, and when to stop

The following clinically significant adverse reactions are described in detail in other sections of the label:

Infusion reaction.
Infections.
Second Primary Malignancies [ see Warnings and Precautions ].
Hepatotoxicity.
Interference with determination of complete response.

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Elotuzumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/elotuzumab
APA 7th: sofidex. (2026, August 2). Elotuzumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/elotuzumab
AMA 11th: Elotuzumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/elotuzumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.